Macitentan and Ambrisentan are recently approved Endothelin A receptor (ETA) antagonist for pulmonary hypertension which shows its effect by preventing the binding of ET1 to both ETA and ETB (Iglarz et al., 2008; Paulis et al., 2015). Here, EDNRA is linked to pulmonary hypertension.